Eclipsys skips into black in Q2

Eclipsys logged a solid second quarter, ended June 30, with quarterly revenues of $134.4 million, compared to $129.8 million for the second quarter of 2009.

On a GAAP [generally accepted accounting principles] basis, net income for the second quarter of 2010 was $1.6 million, compared with net loss of $4.1 million in the second quarter of 2009, according to the Atlanta-based company.

For the six months that ended June 30, new business bookings were $259.4 million, as new and existing customers made investment decisions to meet the meaningful use criteria of the American Reinvestment and Recovery Act. The company said it defines new business bookings as the total amount of all new contracts signed, excluding renewal contracts.

Eclipsys ended the quarter with $143.3 million of cash and $37.3 million in long-term investments.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.